Dmitri Sviridov

Prof. Dmitri Sviridov

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
DSDmitri Sviridov
Dmitri Sviridov
NMNigora Mukhamedova
Nigora Mukhamedova
YMYury I Miller
Yury I Miller
Dmitri Sviridov, Nigora Mukhamedova, Yury I Miller

20 June 2007 in Diabetologia
Verified
Journal Article
Closed access
PDF file
AHA. Hoang
A. Hoang
AMAndrew Murphy
Andrew Murphy
Melinda CoughlanMelinda Coughlan
Melinda Coughlan
MTMerlin Thomas
Merlin Thomas
JFJosephine M Forbes
Josephine M Forbes
DSDmitri Sviridov
Dmitri Sviridov

25 July 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
NMNigora Mukhamedova
Nigora Mukhamedova
AHAnh Hoang
Anh Hoang
DDDragana Dragoljevic
Dragana Dragoljevic
LDLarisa Dubrovsky
Larisa Dubrovsky
TPTatiana Pushkarsky
Tatiana Pushkarsky
DSDmitri Sviridov
Dmitri Sviridov
HIV infection has a profound effect on “bystander” cells causing metabolic co-morbidities. This may be mediated by exosomes secreted by HIV-infected cells and containing viral factors. Here we show that exosomes containing HIV-1 protein Nef (exNef) are rapidly taken up by macrophages releasing Nef into the cell interior. This caused down-regulation of ABCA1, reduction of cholesterol efflux and sharp elevation of the abundance of lipid rafts through reduced activation of small GTPase Cdc42 and decreased actin polymerization. Changes in rafts led to re-localization of TLR4 and TREM-1 to rafts, phosphorylation of ERK1/2, activation of NLRP3 inflammasome, and increased secretion of pro-inflammatory cytokines. The effects of exNef on lipid rafts and on inflammation were reversed by overexpression of a constitutively active mutant of Cdc42. Similar effects were observed in macrophages treated with exosomes produced by HIV-infected cells or isolated from plasma of HIV-infected subjects, but not with exosomes from cells and subjects infected with ΔNef-HIV or uninfected subjects. Mice injected with exNef exhibited monocytosis, reduced ABCA1 in macrophages, increased raft abundance in monocytes and augmented inflammation. Thus, Nef-containing exosomes potentiated pro-inflammatory response by inducing changes in cholesterol metabolism and reorganizing lipid rafts. These mechanisms may contribute to HIV-associated metabolic co-morbidities. HIV infects only a limited repertoire of cells expressing HIV receptors. Nevertheless, co-morbidities of HIV infection, such as atherosclerosis, dementia, renal impairment, myocardial pathology, abnormal haematopoiesis and others, involve dysfunction of cells that can not be infected by HIV. These co-morbidities persist even after successful application of antiretroviral therapy, when no virus is found in the blood. Many co-morbidities of HIV have a common element in their pathogenesis, impairment of cholesterol metabolism. In this study we show that HIV protein Nef released from infected cells in extracellular vesicles is taken up by un-infected (‘bystander’) cells impairing cholesterol metabolism in these cells. This impairment causes formation of excessive lipid rafts, re-localization of the inflammatory receptors into rafts, and triggers inflammation. These mechanisms may contribute to HIV-associated metabolic co-morbidities. Our work demonstrates how a single viral factor released from infected cells into circulation may cause a pleiotropy of pathogenic responses.

1 July 2008 in Atherosclerosis
Verified
Journal Article
Closed access
HRHonor Rose
Honor Rose
JHJennifer F. Hoy
Jennifer F. Hoy
IWIan John Woolley
Ian John Woolley
UTUrbain Tchoua
Urbain Tchoua
MBMichael Bukrinsky
Michael Bukrinsky
DSDmitri Sviridov
Dmitri Sviridov

1 April 2002 in Atherosclerosis
Verified
Journal Article
Closed access
DSDmitri Sviridov
Dmitri Sviridov
PNPaul Nestel
Paul Nestel

1 January 2008 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Closed access
DSDmitri Sviridov
Dmitri Sviridov
NMNigora Mukhamedova
Nigora Mukhamedova
ARAlan T. Remaley
Alan T. Remaley
JCJaye Chin-Dusting
Jaye Chin-Dusting
PNPaul Nestel
Paul Nestel
Plasma concentration of high density lipoprotein (HDL) is one of the most reliable negative risk factors for CVD. There is however convincing experimental and clinical evidence that plasma concentration of HDL does not convey the full picture of atheroprotective properties of HDL. HDL functionality, i.e. the ability of HDL to perform its many atheroprotective functions, is partly independent of HDL concentration and may be as important, if not more important, in determining the atheroprotective capacity of HDL. The capacity of HDL to support cholesterol efflux, its anti-inflammatory, anti-oxidant, anti-thrombotic and other atheroprotective functions are affected dramatically in conditions like coronary artery disease, chronic and acute inflammation, diabetes as well as through various interventions. The mechanisms connecting changes in HDL functionality to HDL structure are only beginning to emerge. Modifications of HDL proteins and lipids, such as advanced glycation and oxidation, changes in HDL composition and size of HDL particles, changes in abundance of various proteins and lipids carried by HDL are among factors affecting HDL functionality. A single common denominator reflecting the multiple HDL functions is yet to be found and may not exist leaving direct measurements of each HDL function as the way to assess atheroprotective capacity of HDL.